Techniques for risk stratification of newly diagnosed patients with chronic myeloid leukemia

Leukemia and Lymphoma

Volumn 52, Issue SUPPL. 1, 2011, Pages 4-11

  Mitchell, Birgitta ^a   Deininger, Michael ^a,b  

^a UNIVERSITY OF UTAH   (United States)

^b UNIVERSITY OF UTAH   (United States)

Author keywords

Drug resistance; myeloid leukemias and dysplasias; prognostication

Indexed keywords

BREAST CANCER RESISTANCE PROTEIN; BUSULFAN; CARRIER PROTEIN; CD34 ANTIGEN; GLYCOPROTEIN P; IMATINIB; MOLECULAR MARKER; ORGANIC CATION TRANSPORTER 1; PROTEIN TYROSINE KINASE;

BLOOD CELL COUNT; CANCER CELL CULTURE; CHRONIC MYELOID LEUKEMIA; CLINICAL ASSESSMENT; COMPARATIVE GENOMIC HYBRIDIZATION; DISEASE COURSE; DRUG DETERMINATION; DRUG RESPONSE; DRUG SENSITIVITY; DRUG TRANSPORT; EVENT FREE SURVIVAL; GENE EXPRESSION; GENE EXPRESSION PROFILING; GENE MUTATION; GENE SEQUENCE; GENETIC ASSOCIATION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; NEOPLASM; OVERALL SURVIVAL; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROGNOSIS; PROGRESSION FREE SURVIVAL; PROTEIN DOMAIN; PROTEIN PHOSPHORYLATION; QUANTITATIVE ANALYSIS; REVIEW; RNA INTERFERENCE; SINGLE NUCLEOTIDE POLYMORPHISM; STRATIFIED SAMPLE;

ANTINEOPLASTIC AGENTS; DRUG RESISTANCE, NEOPLASM; FUSION PROTEINS, BCR-ABL; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, LEUKEMIC; HUMANS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; PIPERAZINES; PROGNOSIS; PROTEIN KINASE INHIBITORS; PYRIMIDINES; RISK; TUMOR MARKERS, BIOLOGICAL;

EID: 79951505293     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428194.2010.546916     Document Type: Review

References (45)

1. Hochhaus A, O'Brien SG, Guilhot F, et al. Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia IRIS 6-year follow-up. Leukemia 2009;23:1054-1061.
2. Sokal JE, Cox EB, Baccarani M, et al. Prognostic discrimina-tion in 'good-risk' chronic granulocytic leukemia. Blood 1984;63:789-799. (Pubitemid 14141296)
3. Druker BJ, Guilhot F, O'Brien SG, et al. Five-year follow-up ofpatients receiving imatinib for chronic myeloid leukemia. N Engl J Med 2006;355:2408-2417. (Pubitemid 44903745)
4. Mahon FX, Belloc F, Lagarde V, et al. MDR1 gene overexpression confers resistance to imatinib mesylate in leukemia cell models. Blood 2003;101:2368-2373. (Pubitemid 36304670)
5. Thomas J, Wang L, Clark RE, Pirmohamed M. Active transport of imatinib into and out of cells: implications for drug resistance. Blood 2004;104:3739-3745. (Pubitemid 39564452)
6. Illmer T, Schaich M, Platzbecker U, et al. P-glycoprotein-mediated drug efflux is a resistance mechanism of chronic myelogenous leukemia cells to treatment with imatinib mesylate. Leukemia 2004;18:401-408. (Pubitemid 38425851)
7. Widmer N, Rumpold H, Untergasser G, Feyet A, Buclin T, Decosterd LA. Resistance reversal by RNAi silencing of MDR1 in CML cells associated with increase in imatinib intracellular levels. Leukemia 2007;21:1561-1562. (Pubitemid 46965298)
8. Galimberti S, Cervetti G, Guerrini F, et al. Quantitative molecular monitoring of BCR-ABL and MDR1 trans-cripts in patients with chronic myeloid leukemia during imatinib treatment. Cancer Genet Cytogenet 2005;162: 57-62. (Pubitemid 41278471)
9. Dulucq S, Bouchet S, Turcq, et al. Multidrug resistance gene (MDR1) polymorphisms are associated with major molecular responses to standard-dose imatinib in chronic myeloid leukemia. Blood 2008;112:2024-2027.
10. Kim DH, Sriharsha L, Xu W, et al. Clinical relevance of a pharmacogenetic approach using multiple candidate genes to predict response and resistance to imatinib therapy in chronic myeloid leukemia. Clin Cancer Res 2009;15:4750-4758.
11. Hatziieremia S, Jordanides NE, Holyoake TL, Mountford JC, Jorgensen HG. Inhibition of MDR1 does not sensitize primitive chronic myeloid leukemia CD34+ cells to imatinib. Exp Hematol 2009;37:692-700.
12. Burger H, van Tol H, Boersma AWM, et al. Imatinib mesylate (STI571) is a substrate for the breast cancer resis-tance protein (BCRP)/ABCG2 drug pump. Blood 2004;104: 2940-2942. (Pubitemid 39434984)
13. Jordanides NE, Jorgensen HG, Holyoake TL, Mountford JC. Functional ABCG2 is overexpressed on primary CML CD34+ cells and is inhibited by imatinib mesylate. Blood 2006;108:1370-1373. (Pubitemid 44232038)
14. Giannoudis A, Davies A, Lucas CM, Harris RJ, Pirmohamed M, Clark RE. Effective dasatinib uptake may occur without human organic cation transporter 1 (hOCT1): implications for the treatment ofimatinib-resistant chronic myeloid leukemia. Blood 2008;112:3348-3354.
15. Hiwase DK, Saunders V, Hewett D, et al. Dasatinb cellular uptake and efflux in chronic myeloid leukemia cells: therapeutic implications. Clin Cancer Res 2008;14:3881-3888.
16. Engler JR, Frede A, Saunders VA, Zannettino ACW, Hughes TP, White DL. Chronic myeloid leukemia CD34+ cells have reduced uptake of imatinib due to low OCT-1 activity. Leukemia 2010;24:765-770.
17. White VA, Saunders VA, Dang P, et al. Most CML patients who have a suboptimal response to imatinib have low OCT-1 activity: higher doses of imatinib may overcome the negative impact of low OCT-1 activity. Blood 2007;110: 4064-4072. (Pubitemid 350248463)
18. White DL, Dang P, Engler J, et al. Functional activity of the OCT-1 protein is predictive oflong-term outcome in patients with chronic-phase chronic myeloid leukemia treated with imatinib. J Clin Oncol 2010;28:2761-2767.
19. Wang L, Giannoudis A, Lane S, Williamson P, Pirmohamed M, Clark RE. Expression of the uptake drug transporter hOCT1 is an important clinical determinant ofthe response to imatinib in chronic myloid leukemia. Clin Pharmacol Ther 2008;83:258-264.
20. White D, Saunders V, Lyons AB, et al. In vitro sensitivity to imatinib-induced inhibition of ABL kinase activity is pre-dictive of molecular response in patients with de novo CML. Blood 2005;106:2520-2526. (Pubitemid 41510828)
21. Picard S, Titier K, Etienne G, et al. Trough imatinib plasma levels are associated with both cytogenetic and molecular responses to standard-dose imatinib in chronic myeloid leukemia. Blood 2007;109:3496-3499. (Pubitemid 46572540)
22. Osborn MP, White DL, Saunders VA, et al. Early dose-escalation in chronic myeloid leukaemia patients with low plasma imatinib levels leads to equivalent BCR-ABL values and drug levels at 6 months to those with optimal drug levels: first analysis from the TIDEL II trial of de-novo patient treated with 600mg imatinib. Blood 2009;114(Suppl. 1): Abstract 1131.
23. White D, Saunders V, Grigg A, et al. Measurement of in vivo bcr-abl kinase inhibition to monitor imatinib-induced target blockade and predict response in chronic myeloid leukemia. J Clin Oncol 2007;25:4445-4451. (Pubitemid 350013851)
24. Schultheis B, Szydlo R, Mahon FX, Apperley JF, Melo JV. Analysis of total phosphotyrosine levels in CD34+ cells from CML patients to predict the response to imatinib mesylate treatment. Blood 2005;105:4893-4895.
25. La Rosee P, Holm-Eriksen S, Konig H, et al. Phospho-CRKL monitoring for the assessment of bcr-abl activity in imatinib-resistant chronic myeloid leukemia or Ph+ acute lymphoblas-tic leukemia patients treated with nilotinib. Haematologica 2008;93:765-769. (Pubitemid 351669319)
26. Hughes T, Deininger M, Hochhaus A, et al. Monitoring CML patients responding to treatment with tyrosine kinase inhibi-tors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results. Blood 2006;108:28-37. (Pubitemid 43990609)
27. Willis SG, Lange T, Demehri S, et al. High-sensitivity detection of bcr-abl kinase domain mutations in imatinib-nä?ve patients: correlation with clonal cytogenetic evolution but not response to therapy. Blood 2005;106:2128-2137. (Pubitemid 41291730)
28. Soverini S, Martinelli G, Rosti G, et al. Abl mutations in late chronic phase chronic myeloid leukemia patients with up-front cytogenetic resistance to imatinib are associated with a greater likelihood of progression to blast crisis and shorter survival: a study by the GIMEMA working party on chronic myeloid leukemia. J Clin Oncol 2005;23:4100-4109. (Pubitemid 46211315)
29. Ernst T, Erben P, Muller MC, et al. Dynamics ofBCR-ABL mutated clones prior to hematologic or cytogenetic resistance to imatinib. Haematologica 2008;93:186-192. (Pubitemid 351397706)
30. Huntly BJP, Reid AG, Bench AJ. Deletions of the derivative chromosome 9 occur at the time of the Philadelphia trans-location and provide a powerful and independent prognostic indicator in chronic myeloid leukemia. Blood 2001;98: 1732-1738.
31. Kreil S, Pfirrmann M, Haferlach C, et al. Heterogeneous prognostic impact of derivative chromosome 9 deletions in chronic myelogenous leukemia. Blood 2007;110:1283-1290. (Pubitemid 47281427)
32. Huntly BJP, Reid AG, Vassiliou G, et al. Imatinib improves but may not fully reverse the poor prognosis of patients with CML with derivative chromosome 9 deletions. Blood 2003;102:2205-2212. (Pubitemid 37122400)
33. Quintas-Cardama A, Kantarjian H, Talpaz M, et al. Imatinib mesylate therapy may overcome the poor prognostic sig-nificance of deletions of derivative chromosome 9 in patients with chronic myelogenous leukemia. Blood 2005;105:2281-2286. (Pubitemid 40387020)
34. Castagnetti F, Testoni N, Luatti S, et al. Deletions of the derivative chromosome 9 do not influence the response and the outcome of chronic myeloid leukemia in early chronic phase treated with imatinib mesylate: GIMEMA CML Working Party analysis. J Clin Oncol 2010;28:2748-2754.
35. Lange T, Gunther C, Kohler T, et al. High levels ofBAX, low levels ofMRP-1, and high platelets are independent predictors of response to imatinib in myeloid blast crisis of CML. Blood 2003;101:2152-2155. (Pubitemid 36302051)
36. Mohty M, Yong ASM, Szydlo RM, Apperley JF, Melo JV. The polycomb group BMI1 gene is a molecular marker for predicting prognosis of chronic myeloid leukemia. Blood 2007;110:380-383. (Pubitemid 47026858)
37. Cilloni D, Messa G, Gottardi E, et al. Sensitivity to imatinib therapy may be predicted by testing Wilms tumor gene expression and colony growth after a short in vitro incubation. Cancer 2004;101:979-988. (Pubitemid 39100432)
38. Crossman LC, Mori M, Hsieh Y, et al. In chronic myeloid leukemia white cells from cytogenetic responders and non-responders to imatinib have very similar gene expression signatures. Haematologica 2005;90:459-464. (Pubitemid 40598077)
39. Frank O, Brors B, Fabarius A, et al. Gene expression signature of primary imatinib-resistant chronic myeloid leukemia patients. Leukemia 2006;20:1400-1407. (Pubitemid 44084053)
40. Radich JP, Dai H, Mao M, et al. Gene expression changes associated with progression and response in chronic myeloid leukemia. Proc Natl Acad Sci USA 2006;103:2794-2799.
41. Oehler VG, Yeung KY, Choi YE, Bumgarner RE, Raftery AE, Radich JP. The derivation of diagnostic markers of chronic myeloid leukemia progression from microarray data. Blood 2009;114:3292-3298.
42. Brazma D, Grace C, Howard J, et al. Genomic profile of chronic myelogenous leukemia: imbalances associated with disease progression. Genes Chromosomes Cancer 2007;46:1039-1050. (Pubitemid 47502843)
43. McWeeney SK, Pemberton LC, Loriaux MM, et al. A gene expression signature of CD34+ cells to predict major cytogenetic response in chronic-phase chronic myeloid leuke-mia patients treated with imatinib. Blood 2010;115:315-325.
44. Yong ASM, Szydlo RM, Goldman JM. Molecular profiling of CD34+ cells identifies low expression of CD7, along with high expression of proteinase 3 or elastase, as predictors of longer survival in patients with CML. Blood 2006;107:205-212. (Pubitemid 43053545)
45. Zheng C, Li L, Haak M, et al. Gene expression profiling of CD34+ cells identifies a molecular signature of chronic myeloid leukemia blast crisis. Leukemia 2006;20:1028-1034. (Pubitemid 43797293)